Afficher la notice abrégée

NSAIDs and COVID-19: A Systematic Review and Meta-analysis

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOORE, Nicholas
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBOSCO-LEVY, Pauline
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTHURIN, Nicolas
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBLIN, Patrick
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDROZ-PERROTEAU, Cecile
dc.date.accessioned2021-11-16T07:59:49Z
dc.date.available2021-11-16T07:59:49Z
dc.date.issued2021-09
dc.identifier.issn0114-5916 (Print) 0114-5916en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/123800
dc.description.abstractEnBACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been discouraged for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, fearing that they could increase the risk of infection or the severity of SARS-CoV-2. METHODS: Original studies providing information on exposure to NSAIDs and coronavirus disease 2019 (COVID-19) outcomes were retrieved and were included in a descriptive analysis and a meta-analysis with Cochrane Revue Manager (REVMAN 5.4), using inverse variance odds ratio (OR) with random- or fixed-effects models. RESULTS: Of 92,853 papers mentioning COVID-19, 266 mentioned NSAIDs and 61 mentioned ibuprofen; 19 papers had analysable data. Three papers described NSAID exposure and the risk of SARS-CoV-2 positivity, five papers described the risk of hospital admission in positive patients, 10 papers described death, and six papers described severe composite outcomes. Five papers studied exposure to ibuprofen and death. Using random-effects models, there was no excess risk of SARS-CoV-2 positivity (OR 0.86, 95% confidence interval [CI] 0.71-1.05). In SARS-CoV-2-positive patients, exposure to NSAIDs was not associated with excess risk of hospital admission (OR 0.90, 95% CI 0.80-1.17), death (OR 0.88, 95% CI 0.80-0.98), or severe outcomes (OR 1.14, 95% CI 0.90-1.44). With ibuprofen, there was no increased risk of death (OR 0.94, 95% CI 0.78-1.13). Using a fixed-effect model did not modify the results, nor did the sensitivity analyses. CONCLUSION: The theoretical risks of NSAIDs or ibuprofen in SARS-CoV-2 infection are not confirmed by observational data.
dc.language.isoENen_US
dc.title.enNSAIDs and COVID-19: A Systematic Review and Meta-analysis
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s40264-021-01089-5en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34339037en_US
bordeaux.journalDrug Safetyen_US
bordeaux.page929-938en_US
bordeaux.volume44en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue9en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03430035
hal.version1
hal.date.transferred2021-11-16T07:59:53Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Drug%20Safety&rft.date=2021-09&rft.volume=44&rft.issue=9&rft.spage=929-938&rft.epage=929-938&rft.eissn=0114-5916%20(Print)%200114-5916&rft.issn=0114-5916%20(Print)%200114-5916&rft.au=MOORE,%20Nicholas&BOSCO-LEVY,%20Pauline&THURIN,%20Nicolas&BLIN,%20Patrick&DROZ-PERROTEAU,%20Cecile&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée